title: Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.
abstract: Pharmacological effects of recombinant human tumor necrosis factor alpha (TNF) were studied in a mouse fibrosarcoma model using magnetic resonance imaging enhanced with a macromolecular contrast agent, albumin(gadolinium-diethylenetriamine pentaacetic acid)35. TNF was administered i.v. in a dose of 150 micrograms/kg, 60 to 80 min prior to imaging. Contrast-enhanced and nonenhanced magnetic resonance images of TNF-treated (n = 10) and untreated (n = 8) Meth A fibrosarcomas were obtained at 2.0 Tesla using T1-weighted spin-echo pulse sequences. Serial images spanning an interval of 60 to 120 min after TNF administration showed that the TNF-treated tumors enhanced significantly more overall than did untreated tumors (43% versus 31%). The most marked differential tumor enhancement was observed in the tumor rim (59% versus 40%). Nontumorous tissue, including muscle and brain, revealed no significant enhancement differences between TNF-treated animals and controls. The observed tumor enhancement corresponded strongly with Evans blue staining; the TNF-treated tumors stained deep blue, while untreated tumors and normal tissues observed did not stain. The different enhancement and Evans blue staining patterns between TNF-treated tumors and untreated tumors are attributed to TNF-induced changes in tumor capillary integrity. The data indicate that TNF effects on tumors include an increased capillary permeability for macromolecules at early times after administration. The ability to detect changes in capillary permeability in vivo using contrast-enhanced magnetic resonance imaging may prove to be clinically useful to monitor tumor response to TNF.
authors.affiliation: Department of Radiology, University of California, San Francisco 94143-0628.
authors.forename: K P
authors.initials: KP
authors.lastname: Aicher
authors.forename: J W
authors.initials: JW
authors.lastname: Dupon
authors.forename: D L
authors.initials: DL
authors.lastname: White
authors.forename: S L
authors.initials: SL
authors.lastname: Aukerman
authors.forename: M E
authors.initials: ME
authors.lastname: Moseley
authors.forename: R
authors.initials: R
authors.lastname: Juster
authors.forename: W
authors.initials: W
authors.lastname: Rosenau
authors.forename: J L
authors.initials: JL
authors.lastname: Winkelhake
authors.forename: R C
authors.initials: RC
authors.lastname: Brasch
mesh_terms: D000818:Animals; D019786:Gadolinium DTPA; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011859:Radiography; D012044:Regression Analysis; D012513:Sarcoma, Experimental / Q000000981:diagnostic imaging* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D009942:Organometallic Compounds; D014409:Tumor Necrosis Factor-alpha; D004369:Pentetic Acid; D019786:Gadolinium DTPA